Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Gsk (GLAXF) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Gsk (GLAXF) over the last 17 years, with Q3 2025 value amounting to -$61.5 billion.

  • Gsk's Total Liabilities fell 613.61% to -$61.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$61.5 billion, marking a year-over-year decrease of 613.61%. This contributed to the annual value of -$59.3 billion for FY2024, which is 20314.13% down from last year.
  • As of Q3 2025, Gsk's Total Liabilities stood at -$61.5 billion, which was down 613.61% from -$59.9 billion recorded in Q2 2025.
  • Gsk's 5-year Total Liabilities high stood at $77.9 billion for Q4 2021, and its period low was -$83.6 billion during Q2 2022.
  • Over the past 5 years, Gsk's median Total Liabilities value was -$59.3 billion (recorded in 2025), while the average stood at -$42.0 billion.
  • Per our database at Business Quant, Gsk's Total Liabilities skyrocketed by 6901.08% in 2022 and then tumbled by 20378.59% in 2024.
  • Quarter analysis of 5 years shows Gsk's Total Liabilities stood at $77.9 billion in 2021, then decreased by 24.6% to $58.7 billion in 2022, then dropped by 2.3% to $57.4 billion in 2023, then tumbled by 203.79% to -$59.5 billion in 2024, then dropped by 3.32% to -$61.5 billion in 2025.
  • Its last three reported values are -$61.5 billion in Q3 2025, -$59.9 billion for Q2 2025, and -$59.3 billion during Q1 2025.